The introduction of ondansetron has revolutionised the treatment of nausea and vomiting which frequently follows cisplatin and other drugs used in the treatment of cancer. However, there remain some patients for whom this 5 HT3 antagonist offers only a partial alleviation of symptoms, particularly on the 3rd and 4th days of treatment. Even when there may be no vomiting, some patients still remain nauseated.
We have demonstrated that stimulation of the P6 acupuncture point (Neiguan) enhances the antiemetic action of the older group of drugs such as metoclopramide, phenothiazines and cyclizine (Dundee et al., 1989b) . This applies to both invasive (needling) and non-invasive (transcutaneous electrical) stimulation (Dundee et al., 1991 (Kris et al., 1985; Schmoll, 1989) and comparable to that in our reported studies with acupuncture (Dundee & Yang, 1990) .
Results
There were no major side effects directly attributed to ondansetron although some reported constipation and headache. Most patients found no difficulty in self stimulation of P6. Figure 1 gives the day to day distribution of nausea scores, severity while ondansetron alone and when combined with TCES. All of the remaining 12 showed a preference in favour of the latter.
Using the binomial sign test this difference is highly significant (P= 0.0005). Three of the four patients who showed no difference in response to the two regimes had a complete absence of sickness with both.
There were no problems in acceptance of the combined regimes.
Discussion
Stimulation of the P6 antiemetic point by either acupuncture or transcutaneous electrical stimulation has been practised widely in our hospital for 4-5 years. All staff and many patients knew why it was being used, but most were not aware of the true nature of our study until it was completed.
The need to elicit Qi was an essential part of our technique and excluded the use of 'dummy TCES' either in the form of a stimulator not generating a pulse or by stimulation of a non-acupuncture point. Furthermore there was no way in which the person doing the assessments could be unaware of the use of TCES.
We have accepted these limitations in our previous studies and feel that they are more than compensated for by our simple scoring scheme which relies heavily on what the patient says and on the views of their attendants. While we cannot entirely divorce ourselves from the thought that the differences might be attributed to active patient involvement; however well controlled randomised studies, both in anaesthesia (Dundee et al., 1989a) and cancer chemotherapy (Dundee et al., 1989b) have shown that 'dummy' acupuncture is ineffective as an antiemetic. Moreover, the important finding is that, irrespective of the mode of action, our patients benefited from the treatment.
Ondansetron has a high reputation as an antiemetic among all our staff and it is interesting to note that incapacitating sickness was only recorded in two patients in this study (Table II) . This differs from our experience with the older group of conventional antiemetics (Dundee et al., 1989b ). However we have an, as yet unconfirmed, clinical impression that its efficacy appears to wane with time. Smith and colleagues (1990) , likewise aware of some of its limitations, have supplemented the use of ondansetron with dexamethasone and have demonstrated additional antiemetic activity by the steroid. Their findings are similar to ours reported here with P6 stimulation.
Ondansetron, while effective, is an expensive drug and since its efficacy can be increased by a simple non-expensive technique such as transcutaneous electrical stimulation of P6 this concept is worthy of further study. Most patients, rather than objecting to its use, like to be able to play some part, albeit a small one, in their own treatment.
